Table 4.
Main effect of cardiovascular disease risk on cortical tau deposition in female APOE ɛ4 carriers but not male carriers
| Predictor variables | EC tau-PET SUVR | ITC tau-PET SUVR | Meta-ROI tau-PET SUVR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Estimate | CI | P-value | Estimate | CI | P-value | Estimate | CI | P-value | |
| Female APOE ɛ4 carriers | |||||||||
| FHS-CVD risk | 0.05 | 0.02–0.08 | 0.002*** | 0.02 | 0.00–0.05 | 0.023* | 0.02 | 0.01–0.04 | 0.013* |
| Time lag | 0.03 | −0.07 to 0.13 | 0.511 | −0.02 | −0.09 to 0.04 | 0.475 | −0.02 | −0.08 to 0.03 | 0.349 |
| Male APOE ɛ4 carriers | |||||||||
| FHS-CVD risk | 0.00 | −0.01 to 0.01 | 0.768 | −0.00 | −0.01 to 0.00 | 0.371 | −0.00 | −0.01 to 0.00 | 0.494 |
| Time lag | 0.12 | −0.01 to 0.25 | 0.064 | 0.07 | −0.02 to 0.15 | 0.107 | 0.07 | −0.00 to 0.13 | 0.062 |
Results from linear regression analysis on sex-stratified groups of APOE ɛ4 carriers revealed a significant main effect of FHS-CVD risk on tau deposition in the EC, ITC and meta-ROI only among female APOE ɛ4 carriers, after adjusting for the time between FHS-CVD risk assessment and tau-PET scan. Significant P-values are presented in bold, where *P < 0.05, **P < 0.01, ***P < 0.005. CI = confidence interval; EC = entorhinal cortex; FHS-CVD risk = Framingham Heart Study cardiovascular disease risk; ITC = inferior temporal cortex; SUVR = standardized uptake value ratio.